ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression

Figure 3 Effects of ASAP3 on gastric cancer tumor growth in vivo. A: Body weight changes of mice after injected with HGC-27 or AGS cells after transfection with short hairpin (sh)-ASAP3 or over-expression (oe)-ASAP3 plasmids for different days; B: Tumor size of mice after injected with HGC-27 or AGS cells after transfection with sh-ASAP3 or oe-ASAP3 plasmids; C: Tumor volume changes of mice after injected with HGC-27 or AGS cells after transfection with sh-ASAP3 or oe-ASAP3 plasmids for different days; D: Hematoxylin and eosin staining of tumor tissues with different treatments. Purple arrow: Irregular cavity; Red arrow: Necrosis; Black arrow: Nuclear fission phase; E: ASAP3 positive cells in tumor tissues of mice after injected with HGC-27 cells after transfection with sh-ASAP3 plasmids using immunofluorescence; F: ASAP3 positive cells in tumor tissues of mice after injected with oe-ASAP3 plasmids using immunofluorescence. ^cP < 0.05 vs short hairpin-negative control-HGC-27 cell. ^dP < 0.05 vs over-expression-negative control-AGS cell. oe: Over-expression; sh: Short hairpin; NC: Negative control.